Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds JP Morgan Upgrades Amphenol to Overweight

JP Morgan Upgrades Amphenol to Overweight

JP Morgan analyst Samik Chatterjee upgrades Amphenol (NYSE:APH) from Neutral to Overweight.

byBenzinga Newsdesk

July 14, 2022

1 minute read

JP Morgan analyst Samik Chatterjee upgrades Amphenol (NYSE:APH) from Neutral to Overweight.

Johnson & Johnson’s TARIS Platform – Goldman Sachs Outlines Potential For The Bladder Cancer Therapy

By Vandana Singh

May 7, 2:31 PM

Johnson & Johnson unveils promising TARIS platform data for bladder cancer treatment, highlighting ease of administration and significant revenue potential.

JNJ

SQZ Biotech’s Cancer Candidate Shows Response At Low Dose In HPV16+ Solid Tumor Patient

By Vandana Singh

March 23, 9:28 AM

SQZ Biotechnologies Company (NYSE:SQZ) announced that a confirmed complete response was observed in the first patient in the lowest-dose cohort of…

SQZ

Bernstein Initiates Coverage On Wendy’s with Outperform Rating, Announces Price Target of $25

By Benzinga Newsdesk

September 8, 5:16 AM

Bernstein analyst Sara Senatore initiates coverage on Wendy's (NASDAQ:WEN) with a Outperform rating and announces Price Target of $25.

WEN

Analyst Ratings

Analyst Expectations for Plains All American’s Future

By Benzinga Insights

September 25, 8:01 AM

Within the last quarter, Plains All American (NASDAQ:PAA) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent…

PAA

JP Morgan Upgrades Amphenol to Overweight

Related Posts

Johnson & Johnson’s TARIS Platform – Goldman Sachs Outlines Potential For The Bladder Cancer Therapy

SQZ Biotech’s Cancer Candidate Shows Response At Low Dose In HPV16+ Solid Tumor Patient

Bernstein Initiates Coverage On Wendy’s with Outperform Rating, Announces Price Target of $25

Analyst Expectations for Plains All American’s Future